Tandem Diabetes Care IncTNDM
What Tandem Diabetes Care Inc does.
References within this Annual Report to “Tandem,” “we,” “our,” “us,” “management,” or the “Company” refer to Tandem Diabetes Care, Inc., together with its wholly-owned subsidiaries.
Tandem Diabetes Care is a global leader in insulin delivery and diabetes technology, specializing in the design, development, and commercialization of advanced solutions that reduce the burden of diabetes management. We serve nearly 500,000 people living with diabetes in more than 25 countries worldwide. Our strategy is to offer flexibility and choice in intelligent insulin delivery systems through an accessible portfolio of market-leading pumps, applications and insights. In support of this strategy, our Tandem pump platforms include t:slim X2 and Tandem Mobi (Mobi), both of which feature Control-IQ+ advanced hybrid closed-loop technology.
Diabetes is a chronic, life-threatening disease for which there is no known cure. It is typically classified as either type 1 or type 2:
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $498.8M | $702.8M | $801.2M | $747.7M | $940.2M | $1.0B |
| Net income | -$34.4M | $15.6M | -$94.6M | -$222.6M | -$96.0M | -$204.7M |
| Free cash flow | -$2.7M | $97.2M | $16.4M | -$58.6M | $5.0M | -$29.7M |
More on TNDM.
- Tandem Diabetes Care Inc summary
- Tandem Diabetes Care Inc financial statements
- Tandem Diabetes Care Inc key metrics
- Tandem Diabetes Care Inc health scores and style box
- Tandem Diabetes Care Inc earnings
- Tandem Diabetes Care Inc dividends
- Tandem Diabetes Care Inc valuation
- Tandem Diabetes Care Inc ownership and insiders
- Tandem Diabetes Care Inc peers
Figures from Tandem Diabetes Care Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.